micafungin sodium · Astellas · NDA 021506
Mycamine
Earliest generic entry, as listed · earliest of 2 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 219518, Yichang Humanwell · 021506-002Approved 24 Feb 2026Detected 25 Oct 2026Historical import
- Generic approved · ANDA 219712, Hisun Pharm Hangzhou · 021506-002Approved 21 Jan 2026Detected 25 Oct 2026Historical import
- Generic approved · ANDA 220296, Aspiro · 021506-002Approved 17 Mar 2026Detected 25 Oct 2026Historical import
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021506 · 002 · RLD · discontinued | injectable, intravenous | EQ 50MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 021506 · 003 · RLD · discontinued | injectable, intravenous | EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |